

CITATION REPORT

List of articles citing

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No

DOI: 10.1111/j.1538-7933.2004.00648.x

Journal of Thrombosis and Haemostasis, 2004, 2, 551-4.

Source: <https://exaly.com/paper-pdf/36774285/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
109	Laboratory monitoring of low-molecular-weight heparin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1004-5	15.4	2
108	Laboratory monitoring of low-molecular-weight heparin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1003	15.4	13
107	Laboratory monitoring of low-molecular-weight heparin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1007	15.4	3
106	Laboratory monitoring of low-molecular-weight heparin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1005-6	15.4	3
105	Laboratory monitoring of low-molecular-weight heparin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1006-7	15.4	4
104	More on: is laboratory monitoring of low-molecular-weight heparin necessary?. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 2276-7	15.4	17
103	Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. 2004 , 44, 270-7		22
102	Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. 2004 , 10, 371-5		10
101	Laboratory monitoring of low-molecular-weight heparin therapy--part II. Monitoring LMWH therapy? For the moment a non-question. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 571-3	15.4	12
100	Laboratory monitoring of low-molecular-weight heparin therapy-part II. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 573-4	15.4	5
99	Laboratory monitoring of low-molecular-weight heparin therapy-part II. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 575-6	15.4	4
98	Laboratory monitoring of low-molecular-weight heparin therapy-part II. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 574-5	15.4	
97	The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 856-62	15.4	65
96	Low molecular weight heparin in pregnancy: current issues. 2005 , 128, 593-601		73
95	Pulmonary embolism: current treatment options. 2005 , 7, 483-90		3
94	Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. 2005 , 10, 251-6		33
93	Coagulation assays. 2005 , 112, e53-60		144

92	Deep vein thrombosis. 2005 , 365, 1163-74		367
91	Dosage of enoxaparin among obese and renal impairment patients. 2005 , 116, 41-50		102
90	State-of-the-art lectures. 2005 , 115, 1-107		5
89	Safety profile of different low-molecular weight heparins used at therapeutic dose. 2005 , 28, 333-49		51
88	An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. 2005 , 37, 234-8		20
87	Acute pulmonary embolism: part II: treatment and prophylaxis. 2006 , 114, e42-7		59
86	Monitoring the effects and managing the side effects of anticoagulation during pregnancy. 2006 , 33, 397-411		8
85	The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. 2006 , 46, 887-94		21
84	Venous Thromboembolism Guidebook: fifth edition. 2006 , 5, 211-27		5
83	Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 83-9	15.4	43
82	Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 372-6	15.4	14
81	Management of venous thromboembolism. 2006 , 53, S80-8		3
80	Perioperative management of patients receiving vitamin K antagonists. 2006 , 53, S113-22		16
79	Microvascular surgery. 2007 , 119, 18e-30e		12
78	No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. 2007 , 3, 469-75		16
77	Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children. 2008 , 122, 867-9		5
76	Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. 2008 , 130, 446-54		39
75	Heparin and low-molecular-weight heparin. 2008 , 99, 807-18		195

74	Differences in the safety profiles of two low-molecular-weight heparins. 2008 , 99, 989-90		1
73	Postoperative care. 2009 , 137-143		2
72	How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin?. 2009 , 101, 325-332		9
71	Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 760-5	15.4	156
70	Assessment and management of high-risk pregnancies in women with thrombophilia. 2009 , 23, 143-7		19
69	Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs. 2009 , 45, 261-7		21
68	New oral antithrombotics: a need for laboratory monitoring. Against. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 627-30	15.4	43
67	Contemporary management of pulmonary embolism: the answers to ten questions. 2010 , 268, 218-31		12
66	Terapia transfusional en cirug�a vascular. 2010 , 371-381		
65	Prevention of venous thromboembolism in obesity. 2010 , 8, 1711-21		80
64	An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. 2010 , 181, 1128-55		211
63	Nonfatal self-poisoning with LMW heparin and the use of antidote. 2010 , 126, e403-5		4
62	Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. 2011 , 128, e125-9		4
61	No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1966-72	15.4	37
60	H�parine de Bas Poids Mol�culaire et insuffisance r�nale: quelle surveillance biologique ?. 2011 , 38, 26-30		
59	Enoxaparin outcomes in patients with moderate renal impairment. 2012 , 172, 1713-8		22
58	External quality assurance for heparin monitoring. 2012 , 38, 632-9		14
57	Surveillance des traitements anticoagulants: d�iv�s h�pariniques et antivitamine K. 2012 , 7, 1-11		

56	Pulmonary embolism and deep vein thrombosis. 2012 , 379, 1835-46	605
55	Principles of Metabolic Surgery. 2012 ,	1
54	32 Monitoring der Antikoagulanzen. 2012 ,	
53	Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients. 2012 , 22, 791	11
52	Pharmacokinetics of the low molecular weight heparin dalteparin in cats. 2012 , 192, 299-303	14
51	Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly. 2013 , 30, 687-99	16
50	A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. 2013 , 138, 4769-76	19
49	Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach. 2013 , 8, 75	21
48	Thromboelastography to monitor the intra-operative effects of low-molecular weight heparin following bridging anticoagulation in a child with normal renal function*. 2013 , 68, 91-6	3
47	Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?. 2013 , 24, 82-4	
46	Diagnosis and Management of Acute Pulmonary Embolism. 2014 , 5, 31-40	
45	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. 2014 , 12, 24	37
44	Enoxaparin: pharmacokinetics and treatment schedule for cats. 2014 , 200, 375-81	8
43	Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. 2014 , 133, 1029-38	4
42	Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. 2015 , 2, 30	22
41	Prévention de la thrombose veineuse chez les patients obèses en réanimation. 2015 , 24, 46-55	
40	Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. 2015 , 71, 25-34	12
39	Handbook for Venous Thromboembolism. 2015 ,	7

38	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. 2015 , 29, 127-36	29
37	6. Pharmaka zur Prophylaxe und Therapie venöser thrombotischer Ereignisse. 2016 , 137-160	
36	Heparin monitoring: clinical outcome and practical approach. 2016 , 74, 637-652	2
35	Contemporary thromboprophylaxis of trauma patients. 2016 , 22, 607-612	6
34	Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial. 2016 , 151, e162069	36
33	Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats. 2016 , 77, 700-7	5
32	Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. 2017 , 13, 1753-1759	5
31	Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels. 2017 , 137, 113-123	3
30	Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism. 2017 , 43, 105-111	20
29	Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review. 2017 , 1, 188-193	3
28	7. Pharmaka zur Prophylaxe und Therapie venöser thrombotischer Ereignisse. 2017 , 161-188	
27	Thromboelastographic changes during laparoscopic fundoplication. 2017 , 12, 19-27	
26	Cross-interference of rivaroxaban and enoxaparin on Berichrom anti-Xa heparin and Biophen direct Xa inhibitor assays. 2018 , 40, e63-e65	4
25	Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. 2018 , 180, 282-291	26
24	European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding. 2018 , 35, 96-107	7
23	Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. 2018 , 13, e0199900	22
22	Perioperative thromboprophylaxis in liver transplant patients. 2018 , 24, 2931-2948	25
21	Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient. 2019 , 34, 877-888	8

20	Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 4-Refining and monitoring antithrombotic therapies. 2019 , 29, 75-87	10
19	From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. 2020 , 39, 100613	13
18	Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin. 2020 , 22, 1312-1320	1
17	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. 2020 , 18, 17	34
16	Emergency medicine misconceptions: Utility of routine coagulation panels in the emergency department setting. 2020 , 38, 1226-1232	5
15	The survival benefit of low molecular weight heparin over unfractionated heparin in pediatric trauma patients. 2021 , 56, 494-499	2
14	Updates in Anticoagulation Therapy Monitoring. 2021 , 9,	7
13	Evaluation of Anticoagulant Monitoring in Pediatric Patients Receiving Enoxaparin for Treatment of Venous Thrombosis. 2021 , 26, 346-351	
12	Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review. 2021 , 47, 824-842	1
11	Heparin - Messias or Verschlimmbesserung?. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2373-2382	5.4 4
10	Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data. 2020 , 58, 1921-1930	9
9	How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005 , 11, 157-62	22
8	Venous Thromboembolism in Spinal Cord Injuries. 2021 , 329-340	
7	Heparinmonitoring. 2010 , 913-924	
6	Antithrombotic Therapy. 2011 , 831-842	
5	Postoperative Management. 2012 , 273-295	
4	Anticoagulation for Venous Thromboembolism: Selecting the Optimal Parenteral and Oral Anticoagulant Regimen. 2015 , 77-91	
3	"In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1 1

2 Deep Vein Thrombosis and Pulmonary Embolism in Spinal Cord Injuries. **2022**, 513-526

1 Systems Biology Approach for Personalized Hemostasis Correction. **2022**, 12, 1903

○